First-line combination therapy of immunotherapy plus anti-angiogenic drug for thoracic SMARCA4-deficient undifferentiated tumors in AIDS: a case report and review of the literature
BackgroundThoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UT) exhibit a notably aggressive phenotype, which is associated with poor patient survival outcomes. These tumors are generally resistant to conventional cytotoxic chemotherapy, thereby limiting the availability of effective treat...
Saved in:
Main Authors: | Xiaoling Wei, Xiangju Xing, Wei Yao, Changzheng Wang, Yajie Xiao, Xianzhi Du |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1473578/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Brief Report: Clinical Characteristics and Outcomes of Patients With Thoracic SMARCA4-Deficient Undifferentiated Tumors
by: Alissa J. Cooper, MD, et al.
Published: (2025-01-01) -
The impact of SMARCA4 loss in non-small cell lung cancer therapy
by: Mariano Lombardi, et al.
Published: (2025-01-01) -
A therapy inactivating the tumor angiogenic factors
by: Cristian Morales-Rodrigo
Published: (2012-11-01) -
SMARCA4 deficiency in small cell lung cancer: A case report and narrative review of the literature
by: Andreas M. Matthaiou, et al.
Published: (2025-01-01) -
SMARCA4-related Coffin-Siris syndrome in newborn: a case report and literature review
by: Yuqian Wang, et al.
Published: (2025-01-01)